Clinical Trials Logo

Myelofibrosis clinical trials

View clinical trials related to Myelofibrosis.

Filter by:

NCT ID: NCT05455294 Recruiting - Clinical trials for Acute Myeloid Leukemia

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: - Venetoclax - Decitabine - Navitoclax

NCT ID: NCT05447260 Recruiting - Myelofibrosis Clinical Trials

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Start date: June 10, 2022
Phase: Phase 4
Study type: Interventional

This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.

NCT ID: NCT05423691 Recruiting - Myelofibrosis Clinical Trials

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

TREG108
Start date: December 27, 2022
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

NCT ID: NCT05371964 Recruiting - Myelofibrosis Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Start date: May 4, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat in combination with ruxolitinib in participants with MF in Part 2.

NCT ID: NCT05320198 Recruiting - Anemia Clinical Trials

Study of DISC-0974 in Participants With Myelofibrosis and Anemia

Start date: June 6, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia.

NCT ID: NCT05280509 Recruiting - Myelofibrosis Clinical Trials

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Start date: June 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.

NCT ID: NCT05279001 Recruiting - Myelofibrosis Clinical Trials

A Safety and Tolerability Study of Jaktinib

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

NCT ID: NCT05233618 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

Start date: July 13, 2022
Phase: Phase 1
Study type: Interventional

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive up to about 9 cycles of treatment with Tag and have a bone marrow biopsy after cycle 4 and about 1 year after HCT.

NCT ID: NCT05123365 Recruiting - Myelofibrosis Clinical Trials

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Start date: January 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

NCT ID: NCT05037760 Recruiting - Myelofibrosis Clinical Trials

Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis

Start date: December 16, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label study to evaluate the safety and efficacy of KER-050 as monotherapy or in combination with ruxolitinib in participants with Myelofibrosis.